Menomune ACYW-135 vaccine

দেশ: নিউ জিলণ্ড

ভাষা: ইংরেজি

সূত্র: Medsafe (Medicines Safety Authority)

সক্রিয় উপাদান:

Neisseria meningitidis Group A polysaccharide 50ug; Neisseria meningitidis Group C polysaccharide 50ug; Neisseria meningitidis Group W135 polysaccharide 50ug; Neisseria meningitidis Group Y polysaccharide 50ug

থেকে পাওয়া:

sanofi-aventis new zealand limited

INN (আন্তর্জাতিক নাম):

Neisseria meningitidis Group A polysaccharide 50 µg

ডোজ:

0.5 mL

ফার্মাসিউটিকাল ফর্ম:

Injection with diluent

রচনা:

Active: Neisseria meningitidis Group A polysaccharide 50ug Neisseria meningitidis Group C polysaccharide 50ug Neisseria meningitidis Group W135 polysaccharide 50ug Neisseria meningitidis Group Y polysaccharide 50ug Excipient: Lactose monohydrate Sodium chloride Purified water

প্যাকেজ ইউনিট:

Combination pack, 1 x ( powder + diluent ), 1 dose unit

শ্রেণী:

Prescription

প্রেসক্রিপশন টাইপ:

Prescription

Manufactured by:

Sanofi Pasteur Inc

থেরাপিউটিক ইঙ্গিত:

Menomune® ACYW-135 is indicated for active immunisation of adults and children older than 2 years against disease caused by Neisseria meningitidis Groups A, C, Y and W-135, the major manifestation being meningococcal meningitis. Vaccination may be considered for the following individuals: · Travellers to countries recognised as having highly endemic or epidemic disease. · Control of epidemics of infection caused by Neisseria meningitidis groups A, C, Y and W-135 in confined communities. · Individuals at particular high risk of acquiring meningococcal infection, including persons with anatomic or functional asplenia. · Close contacts of persons with meningococcal disease due to groups A, C, Y and W-135, as an adjunct to appropriate chemoprophylaxis.

পণ্য সারাংশ:

Package - Contents - Shelf Life: Combination pack, 1 x ( powder + diluent ) - 1 dose units - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) protect from light - Vial, diluent - 0.6 mL - 60 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) - Vial, 1 x monodose powder - 1 dose units - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)

অনুমোদন তারিখ:

1987-04-02

তথ্য লিফলেট

MENOMUNE
®
1
MENOMUNE
® –
A/C/Y/W-135
_Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135
Combined _
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET

This leaflet answers some
common questions about
Menomune vaccine.

It does not contain all available
information. It does not take the
place of talking to your doctor or
pharmacist.

All medicines, including
vaccines, have risks and benefits.
Your doctor has weighed the risks
of you having Menomune vaccine
against the benefits your doctor
expects it will have.
If you have any concerns about this
vaccine, ask your doctor, nurse or
pharmacist.
KEEP THIS LEAFLET. YOU MAY NEED TO
READ IT AGAIN.
WHAT MENOMUNE
VACCINE IS USED FOR
Menomune vaccine is used to help
prevent meningitis or infections
caused by the meningococcal
bacteria groups A, C, Y and W-135.
Menomune vaccine is used to help
prevent meningitis in people likely to
be infected with the meningococcal
bacteria. These include:

travellers to countries where there
is a risk of contracting meningitis

people living in an area where an
outbreak or epidemic of
meningitis has occurred

people in close contact with
someone who has meningitis

people at high-risk of contracting
meningitis such as those who
have their spleen removed or
those whose spleen does not work
properly
HOW MENOMUNE
VACCINE WORKS
Menomune vaccine works by causing
your body to produce its own
protection against infections caused
by meningococcal bacteria groups A,
C, Y and W-135. It does this by
making substances called antibodies
in the blood which fight
meningococcal bacteria. If a
vaccinated person comes into contact
with meningococcal bacteria groups
A, C, Y and W-135, the body is
usually ready to destroy it. Your
body usually takes several weeks
after vaccination to develop
protection against the meningococcal
bacteria. Protection requires one
dose. Most people will produce
enough antibodies against
meningococcal bacteria groups A, C,
Y and W-135. However, as with all
vaccines, 100% protection cannot

পণ্য বৈশিষ্ট্য

MENOMUNE DATA SHEET 
Supercedes version dated: Nov 2007 
Last revised:  7 June 2013 
MENOMUNE
®
 ACYW-135 
_MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP A, GROUP C, GROUP Y
AND _
_GROUP W-135 _
DESCRIPTION 
The vaccine is a freeze-dried preparation of the group specific
antigens from _Neisseria _
_meningitidis_, serogroups A, C, Y and W-135.  
When reconstituted, the vaccine is a clear colourless liquid. 
After reconstitution with the accompanying diluent, each 0.5 mL dose
of vaccine contains:  
ACTIVE INGREDIENTS: 
  Meningococcal polysaccharide Group A  

           50 µg/dose 
  Meningococcal polysaccharide Group C  

           50 µg/dose  
  Meningococcal polysaccharide Group Y  

           50 µg/dose  
  Meningococcal polysaccharide Group W-135 

           50 µg/dose  
EXCIPIENTS:  
  Lactose  

    2.5 mg to 5.0 mg/dose 
  Sodium chloride  

      4.25 to 4.75 mg/dose 
 
Water 
for 
injection 

No preservative is added. 
The manufacture of this product includes exposure to bovine
derived materials.  No evidence 
exists that any case of vCJD (variant Creutzfeldt-Jakob disease,
considered to be the human 
form of bovine spongiform encephalopathy) has resulted from the
administration of any 
vaccine product. 
USES 
_PHARMACOLOGY _
Vaccination with the meningococcal polysaccharides induces the
production of bactericidal 
antibodies which are group specific. That is, the group A
polysaccharide induces antibodies 
only against Group A, and not against any other serogroups. 
Antibody responses to each component of Menomune
®
 ACYW-135 have been similar to the 
responses of the individual polysaccharides administered alone. 
A study using 4 lots of Menomune
® 
ACYW-135 in 150 adults showed at least a four-fold 
increase in bacterial antibodies to all four antigen serogroups in
greater than 90% of